Malaria Vaccine: CSP-rEPA

疟疾疫苗：CSP-rEPA

• 批准号: 8336227
• 负责人: Patrick Duffy
• 金额: $ 167.29万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8336227
• 关键词: Adjuvant; Agonist; Animal Model; Animals; Antibody Formation; Antigens; C-terminal; CTL assay; Carrier Proteins; Cells; Drug Formulations; Erythrocytes; Escherichia coli; Immune; Length; Longevity; Malaria; Malaria Vaccines; Measures; Mediating; N-terminal; Parasites; Peptide Signal Sequences; Plasmodium falciparum; Polysaccharides; Process; Proteins; Recombinant Proteins; Recombinants; Recovery; Rodent; Rodent Model; Signal Transduction; Staging; T cell response; TLR4 gene; Vaccines; base; circumsporozoite protein; cross reacting material 197; design; enzyme linked immunospot assay; immunogenicity; novel; response

rCSP in various lengths were expressed in P. pastoris and E. coli, and processes for scaled recovery were developed. Processes were developed to chemically conjugate the rCSPs to recombinant EPA and CRM197, the carrier proteins with demonstrated capacity of immune enhancement for polysaccharide antigens. B- and T-cell responses, induced by the conjugates in several formulations were evaluated in rodent models. Whereas conjugation significantly increase the antibody responses to the rCSP, a novel adjuvant containing TLR4 agonist significantly increase cellular response in rodents.

不同长度的 rCSP 在毕赤酵母和大肠杆菌中表达，并开发了规模回收工艺。 开发了将 rCSP 与重组 EPA 和 CRM197 进行化学缀合的工艺，这些载体蛋白具有增强多糖抗原免疫能力的能力。 在啮齿动物模型中评估了几种制剂中的缀合物诱导的 B 细胞和 T 细胞反应。 结合显着增加了对 rCSP 的抗体反应，而含有 TLR4 激动剂的新型佐剂则显着增加了啮齿类动物的细胞反应。